Literature DB >> 15754166

[Therapy for systemic urothelial cancer recurrence].

J Lehmann1, M Stöckle.   

Abstract

Detailed data on treating systemic recurrences of urothelial cancer after radical cystectomy and/or radical upper tract surgery are sparse. This review describes the data available from two large clinical phase III trials, one on systemic chemotherapy for metastatic/inoperable urothelial cancer and the other on adjuvant systemic chemotherapy after radical cystectomy for locally advanced bladder cancer. In addition, an overview of contemporary series on metastasectomy for urothelial cancer with palliative as well as curative intent is presented. The impact of therapeutic options for the treatment of systemic urothelial cancer recurrences such as radiotherapy, surgery or systemic first and second line therapy represented by conventional chemotherapy and contemporary target therapy are discussed.

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 15754166     DOI： 10.1007/s00120-005-0786-8

Source DB:  PubMed          Journal:  Urologe A        ISSN： 0340-2592            Impact factor:   0.639


  10 in total

1.  Is there a role for surgery in the management of metastatic urothelial cancer? The M. D. Anderson experience.

Authors:  Arlene O Siefker-Radtke; Garrett L Walsh; Louis L Pisters; Yu Shen; David A Swanson; Christopher J Logothetis; Randall E Millikan
Journal:  J Urol       Date:  2004-01       Impact factor: 7.450

2.  Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients.

Authors:  J P Stein; G Lieskovsky; R Cote; S Groshen; A C Feng; S Boyd; E Skinner; B Bochner; D Thangathurai; M Mikhail; D Raghavan; D G Skinner
Journal:  J Clin Oncol       Date:  2001-02-01       Impact factor: 44.544

3.  Adjuvant cisplatin plus methotrexate versus methotrexate, vinblastine, epirubicin, and cisplatin in locally advanced bladder cancer: results of a randomized, multicenter, phase III trial (AUO-AB 05/95).

Authors:  Jan Lehmann; Margitta Retz; Christina Wiemers; Joachim Beck; Joachim Thüroff; Christoph Weining; Peter Albers; Detlef Frohneberg; Tanja Becker; Peter-Jörg Funke; Peter Walz; Sigrun Langbein; Frank Reiher; Matthias Schiller; Kurt Miller; Stephan Roth; Tilman Kälble; Donald Sternberg; Stefan Wellek; Michael Stöckle
Journal:  J Clin Oncol       Date:  2005-06-06       Impact factor: 44.544

4.  Late oncological occurrences following radical cystectomy in patients with bladder cancer.

Authors:  E Solsona; I Iborra; J Rubio; J Casanova; R Dumont; J L Monrós
Journal:  Eur Urol       Date:  2003-05       Impact factor: 20.096

5.  Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study.

Authors:  H von der Maase; S W Hansen; J T Roberts; L Dogliotti; T Oliver; M J Moore; I Bodrogi; P Albers; A Knuth; C M Lippert; P Kerbrat; P Sanchez Rovira; P Wersall; S P Cleall; D F Roychowdhury; I Tomlin; C M Visseren-Grul; P F Conte
Journal:  J Clin Oncol       Date:  2000-09       Impact factor: 44.544

Review 6.  Gemcitabine and radiotherapy in the treatment of brain metastases from transitional cell carcinoma of the bladder: a case report.

Authors:  Chris Protzel; Uwe Zimmermann; Elke Asse; Gerhard Kallwellis; Klaus Juergen Klebingat
Journal:  J Neurooncol       Date:  2002-04       Impact factor: 4.130

7.  Is there a therapeutic role for post-chemotherapy retroperitoneal lymph node dissection in metastatic transitional cell carcinoma of the bladder?

Authors:  Paul Sweeney; Randall Millikan; Machelle Donat; Christopher G Wood; Arlene Siefker Radtke; Curtis A Pettaway; H Barton Grossman; Colin P N Dinney; David A Swanson; Louis L Pisters
Journal:  J Urol       Date:  2003-06       Impact factor: 7.450

8.  Impact of surgical resection of bladder cancer metastases refractory to systemic therapy on performance score: a phase II trial.

Authors:  T Otto; S Krege; J Suhr; H Rübben
Journal:  Urology       Date:  2001-01       Impact factor: 2.649

9.  Cytoreductive nephrectomy in patients with metastatic renal cancer: a combined analysis.

Authors:  Robert C Flanigan; G Mickisch; Richard Sylvester; Cathy Tangen; H Van Poppel; E David Crawford
Journal:  J Urol       Date:  2004-03       Impact factor: 7.450

10.  An evaluation of gemcitabines differential radiosensitising effect in related bladder cancer cell lines.

Authors:  V K Sangar; R Cowan; G P Margison; J H Hendry; N W Clarke
Journal:  Br J Cancer       Date:  2004-01-26       Impact factor: 7.640
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.